Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Monday, July 30, 2018 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 30, 2018 /PRNewswire/ -- Report ScopeThe key objectives of this study are to: - Review the historical

development of CAR T-cell technology.Download the full report: https://www.reportbuyer.com/product/5480374 - Discuss the principles of chimeric antigen receptor design.- Understand the mechanisms of action associated with CAR T-cell immunotherapy.-
Highlight the ongoing clinical and non-clinical advancements in the field of CAR T-cell therapy.- Access the side effects, disadvantages and limitations of existing CAR T-cell technologies.- Examine the current marketed drugs, including development activities and details of patent expirations.- Determine the production methods for CAR T-cells.- Review the range of joint ventures, collaborations, license and research agreements currently focused on CAR T-cell technology.- Review of the regulatory requirements.- Review the global CAR T-cell therapy market dynamics.- Survey the key players involved in the development of therapeutics for CAR T-cell immunotherapy and provide company profiles. By purchasing this study, the reader will gain:- An improved understanding of the current state and future of this exciting, new and innovative technology.- The latest information on the leading companies engaged in developing this technology, clinical trials being conducted, a review of the status of their intellectual property, product pipelines and insight into their proprietary technologies.- The role and influence of individual countries relating to the development of CAR T-cell therapy and the number of CAR T-cell trials in the U.S. versus China and other countries.- Knowledge of the market potential for the CAR T-cell therapy market and anticipated development of the market. - The analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, an analysis of the incidence and mortality associated with cancers and the target market helps provide the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report.Report Includes- 31 data tables and 41 additional tables- An overview of global market for current research & developments status of Chimeric Antigen Receptor (CAR) T-cell therapy- Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023- Understand market dynamics of CAR T-Cell therapy, along with the growth driving factors, restraints and future scope- Information on competitor initiatives, research and development status of CAR T-cell therapy- Comprehensive company profiles of major players in the market including, Amgen, Avacta Life Sciences Ltd., Bluebird Bio Inc., Novartis Ag, Servier Laboratories, Takeda Pharmaceuticals, and Transgene SASummaryCAR T-Cell Design and EvolutionChimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR-T) are engineered receptors that graft an arbitrary specificity onto an immune effector cell (T-cell).Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T-cell, with transfer of their coding sequence facilitated by retroviral vectors.The receptors are called chimeric because they are composed of parts from different sources.FDA Product ApprovalsThere are two chimeric antigen receptor T-cell (CAR T) therapies currently approved by the U.S. FDA.1. On Aug. 30, 2017, Novartis announced that the U.S. FDA had approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.2. On Oct. 18, 2017, the U.S. FDA approved Yescarta (axicabtagene ciloleucel) (Kite Pharma Inc.), a cell-based gene therapy, for the treatment of adult patients with relapsed or refractory large Bcell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, highgrade B-cell lymphoma and DLBCL arising from follicular lymphoma. Yescarta is not indicated forthe treatment of patients with primary central nervous system lymphoma. It is a CD19-directed genetically modified autologous T-cell immunotherapy.Market Analysis It has been estimated that the global market for CAR T-cell therapies, as defined in the report's market segmentation, was valued at $REDACTED million in 2017 and $REDACTED million in 2018. By the end of the forecast period in 2023, it is predicted that the global market will have increased in value to $REDACTED billion,representing a compound annual growth rate (CAGR) of REDACTED%.Analysis of the global CAR T-cell therapy market shows that North America is by far the largest geographic region in terms of revenue with an estimated REDACTED% global share. The European market is the second largest regional market with an estimated REDACTED% global share and Asia-Pacific has a very small REDACTED% share of the global market in 2018.Download the full report: https://www.reportbuyer.com/product/5480374 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/current-research--developments-status-of-chimeric-antigen-receptor-car-t-cell-therapy-300688466.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store